TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease

Inclusion Criteria: * Patient diagnosed with Mycobacterium abscessus pulmonary disease; * Patients have completed the initial phase of treatment as recommended by the guidelines; * Patients who have given written informed consent * One week prior to enrollment, organ function levels must meet the following criteria: a. Hemoglobin ≥60g/L; b. Neutrophil count ≥0.5×10\^9/L; c. Platelet count ≥60×10\^9/L; d. Serum total bilirubin ≤3 times the upper limit of normal; e. Aspartate aminotransferase ≤3 times the upper limit of normal; f. Alanine aminotransferase ≤3 times the upper limit of normal; g. Creatinine level below 2 times the upper limit of normal or creatinine clearance ≥60mL/min; h. Urea nitrogen ≤200mg/L; i. Urinary protein \<++, with ≥500mg total protein in 24-hour urine if protein is present; j. Blood glucose: within normal range and/or stable blood glucose control in diabetic patients; k. Cardiac function: no history of myocardial infarction within 6 months; no unstable angina; no severe arrhythmia. Exclusion Criteria: * Patients with a drug allergy to the investigational medication; * Patients infected with two or more non-tuberculous mycobacteria, or those with active pulmonary tuberculosis; * Patients with a prior history of pulmonary parenchymal organ transplantation; * Patients with severe conditions such as congenital or acquired immunodeficiency disorders, active malignant tumors (primary or metastatic), or any malignancies requiring chemotherapy or radiotherapy during screening or study; * Patients undergoing dialysis; * Patients with radiation pneumonitis requiring corticosteroid or immunoglobulin pulse therapy, or clinically proven active interstitial lung disease, uncontrolled massive pleural effusion, or pericardial effusion; * Unstable systemic comorbidities (hypertensive crisis, unstable angina, congestive heart failure, myocardial infarction within the past 6 months, severe psychiatric disorders requiring medication, severe hepatic or renal dysfunction, neuropsychiatric conditions such as Alzheimer's disease); * Patients with intestinal dysfunction or malabsorption syndrome; * Pregnant or breastfeeding women; * Patients receiving other investigational drugs within 4 weeks prior to first exposure to the study drug; * Concurrent enrollment in another clinical trial, except for observational (non-interventional) studies or follow-up visits in interventional trials; * Physical examinations or clinical tests that the investigator deems potentially interfering with results or increasing treatment-related complications.